Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan lifts Rolls-Royce price target

(Sharecast News) - JPMorgan Cazenove lifted its price target on Rolls-Royce on Monday to 1,040p from 900p, pointing to improving prospects in multiple end markets. The bank nudged up its 2026-2028 earnings per share estimates by 1-2%, with better prospects in most markets, partly offset by the weaker US dollar FX rate.

"We think this is a good outcome given that we recently had to lower our estimates for some other European Civil Aerospace companies due to the weaker US dollar," it said.

JPM said it was increasing the multiples-based price target as it applies higher target multiples to its free cash flow estimates.

"In recent years we have grappled with how to value RR, given that its medium-term FCF is boosted by its business model (RR collects significant advance payments on long term service agreements)," it said.

"However, even if we apply a haircut to our FCF estimates for these advance payments, RR is still trading at a very large discount to Safran and GE on FCF yield."

JPM said it sees scope for this discount to reduce if RR continues to deliver strong results, as it expects.

The bank maintained its 'overweight' rating on the shares.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.